Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma.

Evan CantorKyle WierzbickiRohinton S TaraporeKarthik RaviChase ThomasRodrigo CartaxoViveka Nand YadavRamya RavindranAmy K BruzekJack WaddenVishal JohnClarissa May BabilaJessica R CummingsAbed Rahman KawakibiSunjong JiJohanna RamosAlyssa PaulDustin WallingMarcia LeonardPatricia RobertsonAndrea FransonRajen ModyHugh J L GartonSriram VennetiYazmin OdiaCassie KlineNicholas A VitanzaSoumen KhatuaRomain MuellerJoshua E AllenSharon L GardnerCarl J Koschmann

Published in: Neuro-oncology (2022)

Our work demonstrates the feasibility and potential utility of serial cf-tDNA in both plasma and CSF of DMG patients to supplement radiographic monitoring. Patterns of change in H3K27M VAF over time demonstrate clinical utility in terms of predicting progression and sustained response and possible differentiation of pseudo-progression and pseudo-response.

Keyphrases

cell free
cystic fibrosis
end stage renal disease
circulating tumor
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
low grade
climate change
circulating tumor cells